We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+41.63%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.37B
AUM Growth
+$500M
(+27%)
Cap. Flow
+$109M
Cap. Flow
% of AUM
4.61%
Top 10 Holdings %
Top 10 Hldgs %
58.56%
Holding
56
New
7
Increased
13
Reduced
6
Closed
6
Avg Time Held
1.2
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CG Oncology
CGON
|
+$31.4M |
| 2 |
Oric Pharmaceuticals
ORIC
|
+$23.8M |
| 3 |
BridgeBio Pharma
BBIO
|
+$23.5M |
| 4 |
Soleno Therapeutics
SLNO
|
+$18.6M |
| 5 |
PepGen
PEPG
|
+$17.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$16.1M |
| 2 |
Dyne Therapeutics
DYN
|
+$15.8M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
+$14.1M |
| 4 |
Apogee Therapeutics
APGE
|
+$11.2M |
| 5 |
89bio
ETNB
|
+$11.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.77% |
| 2 | Miscellaneous | 0.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Structure Therapeutics
GPCR
$1.58B
| $27M | 1.14% |
629,194
+312,004
| +98% | +$13.2M |
2023 Q4
1 quarter
|
|
27
Trevi Therapeutics
TRVI
$1.72B
| $25.5M | 1.07% |
7,381,090
| – | – |
2022 Q2
7 quarters
|
|
28
Silence Therapeutics
SLN
$582M
| $24.8M | 1.05% |
1,148,591
+267,418
| +30% | +$5.81M |
2022 Q1
8 quarters
|
|
29
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $22.9M | 0.97% |
1,455,837
+434,037
| +42% | +$6.68M |
2023 Q2
3 quarters
|
|
|
30
PepGen
PEPG
$176M
| $22.1M | 0.93% |
+1,502,788
| New | +$17.7M |
2024 Q1
0 quarters
|
|
31
AnaptysBio
ANAB
$1.45B
| $20.3M | 0.85% |
899,700
| – | – |
2022 Q1
8 quarters
|
|
32
Savara
SVRA
$974M
| $19.9M | 0.84% |
4,000,000
| – | – |
2023 Q3
2 quarters
|
|
33
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $16.6M | 0.7% |
393,000
| – | – |
2022 Q1
8 quarters
|
|
34
Agios Pharmaceuticals
AGIO
$1.93B
| $15.3M | 0.65% |
523,166
| – | – |
2023 Q3
2 quarters
|
|
35
DELISTED
Adverum Biotechnologies
ADVM
| $15.1M | 0.64% |
+1,069,244
| New | +$16.3M |
2024 Q1
0 quarters
|
|
36
Puma Biotechnology
PBYI
$543M
| $14.9M | 0.63% |
+2,816,294
| New | +$15.2M |
2024 Q1
0 quarters
|
|
37
Tyra Biosciences
TYRA
$1.31B
| $13.6M | 0.58% |
832,220
-194,200
| -19% | -$3.19M |
2022 Q1
8 quarters
|
|
38
DELISTED
Applied Therapeutics
APLT
| $13.3M | 0.56% |
+1,952,857
| New | +$8.77M |
2024 Q1
0 quarters
|
|
39
Allogene Therapeutics
ALLO
$460M
| $12.8M | 0.54% |
+2,867,750
| New | +$12M |
2024 Q1
0 quarters
|
|
40
Arvinas
ARVN
$468M
| $11.8M | 0.5% |
285,331
| – | – |
2022 Q1
8 quarters
|
|
|
41
DELISTED
89bio
ETNB
| $11.6M | 0.49% |
1,000,000
-1,000,000
| -50% | -$11.1M |
2023 Q4
1 quarter
|
|
42
Acadia Pharmaceuticals
ACAD
$3.39B
| $8.7M | 0.37% |
470,338
-260,579
| -36% | -$6.46M |
2022 Q3
6 quarters
|
|
43
Cogent Biosciences
COGT
$5.12B
| $6.29M | 0.27% |
936,576
-1,058,691
| -53% | -$6.54M |
2022 Q1
8 quarters
|
|
44
Intellia Therapeutics
NTLA
$1.59B
| $5.6M | 0.24% |
203,684
| – | – |
2022 Q1
8 quarters
|
|
45
NewAmsterdam Pharma Warrant
NAMSW
| $5.52M | 0.23% |
500,333
| – | – |
2022 Q4
5 quarters
|
|
46
AN2 Therapeutics
ANTX
$136M
| $4.51M | 0.19% |
1,388,889
| – | – |
2023 Q3
2 quarters
|
|
47
Metagenomi Therapeutics
MGX
$31.9M
| $2.94M | 0.12% |
+279,025
| New | +$3.21M |
2024 Q1
0 quarters
|
|
48
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $2.65M | 0.11% |
1,030,878
| – | – |
2022 Q1
8 quarters
|
|
49
DELISTED
bluebird bio
BLUE
| $2.19M | 0.09% |
85,495
| – | – |
2022 Q3
6 quarters
|
|
50
Aclaris Therapeutics
ACRS
$512M
| $328K | 0.01% |
264,377
| – | – |
2022 Q1
8 quarters
|
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q1 2024 Portfolio in Review
As of Q1 2024, Frazier Life Sciences Management held 56 positions worth $2.37B, up 27% from $1.87B the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Frazier Life Sciences Management deployed $109M of net new capital in Q1 2024, opening 7 new positions and adding to 13 existing holdings. Its largest new stake was CG Oncology: 770,000 shares worth $33.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was 89bio, an estimated $11.1M trimmed.
- Frazier Life Sciences Management's largest Q1 2024 buy was CG Oncology: 770,000 shares worth $33.8M.
- Frazier Life Sciences Management added most to Oric Pharmaceuticals in Q1 2024, an estimated $23.8M increase.
- Frazier Life Sciences Management's biggest Q1 2024 reduction was 89bio, cutting an estimated $11.1M.
- Frazier Life Sciences Management fully exited Madrigal Pharmaceuticals in Q1 2024, selling an estimated $16.1M.
- Frazier Life Sciences Management's ten largest holdings make up 59% of its $2.37B portfolio in Q1 2024.
- Frazier Life Sciences Management opened 7 new positions and closed 6 in Q1 2024.
- Frazier Life Sciences Management's portfolio value rose 27% quarter-over-quarter to $2.37B.
Based on Frazier Life Sciences Management's 13F filing for Q1 2024, filed 15 May 2024.